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Recruitment of Female SexWorkers inHIV Prevention Trials:
Can Efficacy Endpoints Be Reached More Efficiently?
Daniel Wood, PhD,* Kathryn E. Lancaster, PhD, MPH,† Marie-Claude Boily, PhD,‡
Kimberly A. Powers, PhD,§ Deborah Donnell, PhD,*k Myron S. Cohen, MD,† and
Dobromir T. Dimitrov, PhD*¶
Background/Setting: Randomized controlled trials (RCTs) of
HIV biomedical prevention interventions often enroll participants
with varying levels of HIV exposure, including people never
exposed to HIV. We assessed whether enrolling larger proportion
of participants with consistently high exposure to HIV, such as
female sex workers (FSWs), might reduce trial duration and improve
the accuracy of product efficacy estimates in future HIV
prevention trials.
Methods: We used an individual-based stochastic model to
simulate event-driven RCTs of an HIV prevention intervention
providing 80% reduction in susceptibility per act under different
proportions of FSW enrolled. A 5% annual dropout rate was
assumed for both FSW and non-FSW in our main scenario, but
rates of up to 50% for FSW were also explored.
Results: Enrolling 20% and 50% FSW reduced the median-
simulated trial duration from 30 months with 0% FSW enrolled to
22 months and 17 months, respectively. Estimated efficacy increased
from 71% for RCTs without FSW to 74% and 76% for RCTs with
20% and 50% FSW enrolled, respectively. Increasing the FSW
dropout rate to 50% increased the duration of RCTs by 1–2 months
on average and preserved the gain in estimated efficacy.
Conclusions: Despite the potential logistical challenges of recruit-
ing and retaining FSW, trialists should revisit the idea of enrolling
FSW in settings where HIV incidence among FSW is higher than
among non-FSW. Our analysis suggests that enrolling FSW would
increase HIV incidence, reduce trial duration, and improve efficacy
estimates, even if the annual dropout rate among FSW participants
is high.
Key Words: HIV prevention, clinical trial, female sex workers,
mathematical modeling
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INTRODUCTION
New biomedical modalities for HIV prevention are
currently undergoing testing in randomized controlled trials
(RCTs) among individuals believed to be at-risk of HIV. The
design of these RCTs typically assumes a common effectiveness
at all levels of HIV acquisition risk, irrespective of exposure
level. However, if participants with low or no HIV exposure are
enrolled—a group in which an effective intervention cannot
demonstrate an effect—then attenuation of observed treatment
efficacy and thereby reduced efficiency of RCTs will occur.
Here, we explore the extent to which enrolling large fractions of
participants from populations with consistently high exposure to
HIV, such as female sex workers (FSWs), may improve the
efficiency of an RCT and more accurately estimate product
efficacy in future HIV prevention trials.
Globally, FSWs are disproportionately infected with
HIV.1 Within sub-Saharan Africa, the HIV prevalence among
FSW is nearly 40%2 with regional estimates of approximately
70%.3,4 Annual HIV incidence among FSW in sub-Saharan
Africa ranges from 0.90 per 100 person-years [95% confi-
dence interval (CI): 0.24 to 1.58] in Burkina Faso to 9.8 (95%
CI: 7.10 to 15.90) in Zimbabwe.5–14 Despite FSW being at
high risk of HIV acquisition, few recent HIV prevention trials
have purposely enrolled HIV-uninfected FSW.15 Most large,
multisite HIV prevention trials targeting women do not report
the proportion of study participants practicing sex work or
transactional sex, yet of those trials that do, the majority report
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less than 10% engaging in such practices.15–17 Given their
considerable risk of HIV acquisition, FSWs would clearly
benefit from effective prevention interventions and thus should
be included in prevention trials.
Our previous modeling analysis18 suggested that most
women enrolled in HIV prevention trials in high-prevalence
settings remain unexposed to HIV. If exposure to HIV is
concentrated in a relatively small but unmeasured fraction of
trial participants, this unobservable heterogeneity in HIV
acquisition risk will introduce frailty selection bias—where only
participants who have infected partners acquire HIV. Women
with a low rate of partnership exchange are either repeatedly or
never exposed to HIV during follow-up, depending on the HIV
status of their partners. Therefore, the HIV incidence among
repeatedly exposed women will be substantially higher than the
overall incidence in the cohort. If a highly effective prevention
product is tested, the risk of infection will be significantly
reduced among exposed women in the active arm. Because
highly exposed individuals will become infected and removed
from follow-up more quickly in the placebo than in the active
arm, there will be a growing imbalance in HIV exposure risk
between trial arms over time, even if the arms were perfectly
balanced at the time of randomization.19 As a result, the product
efficacy estimated in RCTs with concentrated HIV exposure is
lower compared with trials with increased prevalence of HIV
exposure.19,20 Enrolling high-risk women who in behavioral
questionnaires report more frequent change of partners may
increase the proportion of participants exposed to HIV in
settings with high male HIV prevalence. However, it is unlikely
to reduce substantially the imbalance in HIV exposure because
the majority of high-risk women still have large number of sex
acts with few partners. We argue that enrolling FSWs, who have
few sex acts with a large number of partners, will have more
profound effect on the trial results.
Here, we explore the extent to which enrolling different
proportions of FSWmay reduce the expected duration of trials as
well as limit attenuation of efficacy estimates, and thereby
increase the likelihood of correctly identifying effective bio-
medical products. We compared scenarios in which FSWs have
a high volume of clients and consistent condom use (eg,
professional FSWs) with scenarios in which FSWs practice sex
work less frequently with fewer clients (eg, part time FSWs).
Although we hypothesize that enrolling FSWs may improve trial
efficiency, retaining FSWs in trials over long follow-up periods
may be challenging. Thus, we additionally investigated the




We modified a previously published stochastic individual-
based model18,21 to simulate randomized placebo-controlled
trials of HIV prevention interventions in women, assuming
enrollment of different FSW proportions. The model was
designed to reproduce the sexual behavior of a cohort of 3600
sexually active HIV-uninfected women in high HIV prevalence
settings, accrued using the enrollment criteria of the recently
concluded MTN 020 ASPIRE trial22 over a 1-year period and
randomized in a 1:1 ratio to active or placebo arms. We
simulated 2 types of RCTs (Table 1). The primary design of
interest was an event-driven trial, that is, a trial that concludes
when a prespecified number of infections have occurred. The
secondary design of interest (explored in the Supplemental
Digital Content, http://links.lww.com/QAI/B98) was an RCT
where all participants were followed for a fixed period of 3 years.
The women in the cohort were divided into 3
categories: FSW, low-risk non-FSW, and high-risk non-
FSW, with low-risk and high-risk groups defined by
propensity for concurrent partnerships. Every woman
(FSWs and non-FSWs) in the main scenario could be
involved in 2 types of steady partnerships: (1) short term
with expected duration 6–12 months in which condoms
were used more frequently; (2) long term with expected
duration of 10 years in which condoms were used less
frequently. The partners’ and clients’ characteristics, their
baseline HIV and treatment status as well as their risk of
HIV acquisition outside the partnership were simulated
according to data-derived parameters from published
studies on sexual behavior patterns and HIV transmission
in South Africa.23–25 The frequency of sexual acts was
assigned at the initiation of each partnership and remained
constant for its duration. Similar coital frequency was
assumed for long- and short-term couples with sexual acts
occurring randomly in time. An average of 20% of all
partnerships were assumed to practice anal sex and with an
average of 40% of all sex acts to be anal.23
A complete description of the model, model parameters,
and the values used in the analysis is included in the
Supplemental Digital Content, http://links.lww.com/QAI/B98.
HIV Transmission and Prevention
The HIV acquisition risk per sex act was determined
by the stage of infection (acute, asymptomatic, or late) of
TABLE 1. Description of All Scenarios Explored in the Analysis
Parameter Varied Values Explored
RCT design Event-driven trial targeting 120
infections, trial with uniform
3-year follow-up
True efficacy per act
(% reduction of susceptibility per
HIV-exposed act)
50% and 80%
Percentage of participants who are
FSW
0%, 20%, 50%, and 100%
HIV incidence among FSW due to
sex work
High (4–8%). Overall incidence








5%, 10%, 20%, and 50%
Values in bold are used in the main set of simulations. Remaining values are
explored in secondary scenarios for sensitivity analyses.
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the infected partner or client, his treatment status, the type
of act (vaginal or anal), and the use or nonuse of a condom.
The model was calibrated to reproduce annual HIV
incidence from sex work in the range 4%–8% among FSW.
The efficacy of imperfect biological interventions
can be conceptualized as either partially protective in all
people or fully protective in only a proportion of people.
We assumed partial protection to everybody using the
product at every HIV exposure.26–28 For simplicity, we
refer to this protection as the “true efficacy per act” in this
article. In our main scenario, we simulated event-driven
RCTs of a biomedical intervention with a time-invariant
80% true efficacy per act (reducing susceptibility to HIV
infection per sexual contact with an HIV-infected man).
Alternatively, we assessed the potential importance of
FSW enrollment when the product is only moderately
effective (50% true efficacy per act). The “estimated
efficacy” in the RCTs was calculated as 1 minus the
incidence rate ratio (IRR) of acquiring HIV, defined as the
ratio of the HIV incidence rate in the active vs control arm.
Trial Simulations and Outcomes of Interest
We explored enrollment of different proportions of
FSW (0%, 20%, 50%, and 100%) assuming 9.5% median
HIV incidence among FSW and 2.8% median annual HIV
incidence among non-FSW in the cohort (Table 1). The
annual retention rate target of 95% (5% dropout rate) was
used in the main scenario among both FSW and non-FSW. To
assess the importance of FSW retention, we considered
alternative scenarios with dropout rates up to 50%
among FSW.
The main outcomes of interest were trial duration and
estimated efficacy in the simulated RCTs. We also compared
the annual HIV incidence and total follow-up time by arm
across scenarios. Outcomes were compared across scenarios
with different proportions of FSW enrolled. For each
scenario, we present median value, interquartile range, and
90% uncertainty interval (UI) based on 1000 RCTs simulated
per scenario.
Sensitivity Analyses
We conducted additional analyses to help understand
the impact of FSW enrollment in RCTs. We investigated
alternative scenarios in which recruited FSWs had less
frequent contacts with clients resulting in substantially lower
HIV incidence (1%–2%) because of sex work. We compared
cohorts with the same overall HIV incidence rate in the
control arm but different proportion of FSW enrolled. We
also simulated RCTs where participants were enrolled
simultaneously and followed for a fixed duration of 3 years.
RESULTS
Impact of FSW Enrollment on HIV Incidence
In the simulated trials, enrolling professional FSW
participants resulted in increasing HIV incidence rates
(Fig. 1A). For a cohort without FSW, the median annual
HIV incidence was 2.8% in the control arm. Simulated trials
with 20% FSW participants resulted in a median annual HIV
incidence of 4.2% in the control arm. The median annual HIV
incidence within the control arm further increased to 6.1%
with 50% FSW participants enrolled and to 9.5% with
a cohort of all FSW participants. Within the active interven-
tion arm, the median annual HIV incidence was 0.8% among
a cohort without FSW. Enrolling 20% and 50% FSW
participants increased the median annual HIV incidence to
1.1% and 1.4%, respectively, in the active arm. Simulated
trials with all FSW participants resulted in a median annual
HIV incidence in the active arm of 2.1%.
Impact of FSW Enrollment on Trial Duration
for Different HIV Incidence Rates
Our simulations suggested that enrolling professional
FSW participants substantially reduced the expected trial
duration (Fig. 1B) because of the overall increase in HIV
incidence. When compared with trials without FSW, enrolling
20% FSW reduced the median trial duration by 27% from 30
to 22 months. The total follow-up time needed to reach the
targeted number of infections was reduced by 31% from 6800
to 4710 person-years (Fig. 1C). Under the simulated scenarios
with targeted FSW enrollment, 76% of the trials enrolling
20% FSW were completed within 2 years after the start of
enrollment compared with only 18% when no FSWs were
enrolled. The trial duration was further shortened as the
proportion of enrolled FSW increased. With 50% FSW, the
median trial duration was 17 months, with 100% of the
simulated trials coming to completion within 2 years. The
total expected follow-up time in this scenario was reduced by
more than 50% compared with simulations with no FSW.
Among the trials where only FSW participants were enrolled,
the median trial duration was 13 months.
The extent to which trial duration was shortened was highly
dependent on the difference in HIV incidence among FSW and
non-FSW populations because it determined the increases in the
overall HIV incidence when more FSWs were enrolled. Simu-
lated RCTs in which FSW incidence (4%) was only marginally
higher than the non-FSW incidence (2.8%) demonstrated that
enrolling 20% and 50% FSW shortened trial duration by only 1
and 3 months in comparison with trials without FSW (Supple-
mental Digital Content Fig. S1, http://links.lww.com/QAI/B98).
Impact of FSW Enrollment on Estimated
Efficacy in RCTs
Enrolling FSW may provide additional advantages
when the biomedical intervention is not perfect (true efficacy
per act ,1) by reducing the extent to which efficacy
estimated in RCTs underestimates the true efficacy resulting
from frailty effects. The estimated efficacy of the HIV
prevention intervention was projected to increase, as the
proportion of enrolled FSW participants increased (Fig. 1D).
In trials without FSW participants, the median estimated
efficacy was 71% (90% UI: 62.4%–78.8%), nearly 10
percentage points below the assumed true efficacy per act
Wood et al J Acquir Immune Defic Syndr  Volume 77, Number 4, April 1, 2018
352 | www.jaids.com Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
.
of 80%. When enrolling 20% or 50% FSW participants, the
estimated efficacy increased to 74% (90% UI: 65.5%–80.1%)
or 76% (90% UI: 68.6%–82.4%), respectively. In trials where
only FSW participants were enrolled, the median estimated
efficacy was 78% (90% UI: 70.4%–84.3%) with the residual
difference from 80% because of HIV exposure in steady
partnerships. Alternative scenarios assuming that FSWs had
no partners other than clients showed average estimated
efficacy equal to the true efficacy per act (Supplemental
Digital Content Fig. S2A, http://links.lww.com/QAI/B98).
In contrast to trial duration, differences in estimated
efficacy cannot be attributed to higher HIV incidence among
FSW. We simulated a cohort with 0% FSW in which the control
arm HIV incidence was 61 infections per 1000 persons years,
identical to the control arm incidence in the main scenario with
50% FSW participants (Fig. 2A). Although both trials were
projected to have a similar duration of 17 months, the estimated
efficacy was still 9% points lower in the trials with no FSW (Fig.
2B). Additional sensitivity analyses confirmed that increased
prevalence of participants with consistently high HIV exposure is
the likely reason for the improved efficacy estimates in trials
enrolling FSWs rather than differences in HIV incidence rates
between FSW and non-FSW and shorter trial duration. Scenarios
assuming comparably low-HIV incidence of 2.8% among FSW,
non-FSW, and FSW having no partners other than clients also
showed differences in efficacy estimates up to 9 percentage
points because of FSW enrollment (Supplemental Digital
Content Fig. S2, http://links.lww.com/QAI/B98). Differences in
estimated efficacy remained unaffected if all participants were
simultaneously enrolled and followed for a fixed duration of 3
years (Supplemental Digital Content Fig. S3, http://links.lww.
com/QAI/B98).
How Important Is It to Retain FSW in
the Trial?
Projected improvements in trial duration and estimated
efficacy in RCTs were mostly retained in sensitivity analyses
where we modeled higher dropout rates among FSW participants,
assuming dropout was independent of arm. Scenarios with 20%
and 50% FSW participants showed that HIV incidence in the
control arm was reduced slightly when dropout rates among FSW
increased to as much as 50% (Supplemental Digital Content Fig.
S4, http://links.lww.com/QAI/B98). RCTs were expected to
continue only 2 months longer when 50% of FSWs were lost
to follow-up annually compared with 5% in the main scenario
FIGURE 1. Projected impact of enrolling professional FSWs in prevention RCTs. A, Projected HIV incidence rate by arm; (B) trial
duration; (C) total follow-up time by arm; and (D) estimated efficacy. Fixed true efficacy of 80% in reducing HIV susceptibility per
exposed act and 5% annual dropout rate are assumed over the course of the trial. Box plots and whiskers represent quartile ranges
and 90% UI, reflecting the estimated variation over 1000 trials simulated.
J Acquir Immune Defic Syndr  Volume 77, Number 4, April 1, 2018 FSW Recruitment in HIV Prevention Trials
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 353
(Fig. 3A). The likelihood that the RCT with 20% FSW
participants enrolled would continue longer than 2 years increased
from 24% to 30% when 20% instead of 5% FSWs were lost to
follow-up annually. The estimated efficacy was essentially
unaffected by the lower retention rate provided that women
who dropped out were well balanced between arms (Fig. 3B).
What if the True Efficacy of the Biomedical
Study Product Is Lower?
We also assessed the benefits of enrolling FSW in
scenarios where true efficacy per act was 50% compared
with our main scenario where the true efficacy was fixed at
80% (Fig. 4). As expected, lower true efficacy per act led to
higher HIV incidence in the active arms of the simulated
trials and as a result, RCTs were completed faster even
without FSW participants. Enrolling 20% and 50% high-risk
FSWs further shortened the trial by 25% and 38%,
respectively. The estimated efficacy in RCTs without FSW
was 40%, which is 10 percentage points lower than true
efficacy, a relative loss of 20%. Almost 22% of the RCTs
without FSW were expected to report nonsignificant product
efficacy and almost 80% of the RCTs were unable to rule out
efficacy below 25%, a predefined goal of prevention trials
such as VOICE, Partners PrEP, and ASPIRE.29–31 If 20%
and 50% of the participants were FSW, efficacy estimates
improved to 43% and 45% and the proportion of inconclu-
sive trials was reduced to 12% and 9%, respectively
(Fig. 4D).
DISCUSSION
Successful and timely completion of an event-driven
RCT depends on sufficiently high HIV incidence within the
enrolled cohort. All HIV prevention RCTs include enrollment
criteria designed to ensure that study subjects demonstrate
sufficient HIV acquisition risk to justify enrollment. To this
FIGURE 2. Simulations of trials without FSW and 50% FSWs with similar overall HIV incidence in the control arm. A, HIV incidence
rate by arm and (B) estimated efficacy in RCT. Fixed true efficacy of 80% in reducing HIV susceptibility per exposed act and 5%
annual dropout rate are assumed over the course of the trial. Bars and range plots represent median estimates and 90% UI,
reflecting the estimated variation over 1000 trials simulated.
FIGURE 3. Simulations of trials with different dropout rates among FSW. A, Trial duration and (B) estimated efficacy in RCT. Fixed
true efficacy of 80% in reducing HIV susceptibility per exposed act and 5% annual dropout rate among non-FSW are assumed
over the course of the trial. Bars and range plots represent median estimates and 90% UI, reflecting the estimated variation over
1000 trials simulated.
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end, our model shows that including a substantial number of
high-risk FSW in an HIV prevention trial will lead to
a significant reduction in trial duration.
More importantly, our model predicted that enrolling
FSW with consistently high exposure to HIV would also
provide a more accurate estimate of the efficacy of an
intervention. Ideally, we would be able to quantify the
reduction in the risk of HIV acquisition per HIV-exposed
sex act, a measure that would be independent of the sexual
behavior of each individual. Efficacy estimates from RCTs
based on the cumulative incidence ratio (CIR) or IRR
underestimate the true efficacy per act of an imperfect
biomedical prevention for at least 2 reasons. First, a high
magnitude of exposure, defined as a high number of HIV
exposures per exposed participant, may reduce the observed
CIR-based efficacy because the risk of infection accumulates
with each additional challenge in both the biomedical product
and the placebo arms.32 The IRR-based efficacy (as used in
our analysis) theoretically provides a more accurate estimate
of true efficacy because it accounts for the differences in
follow-up time between arms. However, downward biases
also incur with IRR-based efficacy, particularly if testing
intervals are long and the frequency of sex acts is high.
Second, the concentration of HIV exposure in only
a portion of trial participants may attenuate CIR- and
IRR-based efficacy estimates because of inclusion of
persons with no exposure to HIV, to whom the biomedical
product provides no actual protection. Our analysis con-
firmed that efficacy estimated in RCTs with HIV exposure
concentrated in only a portion of participants is lower
compared with trials in cohorts with more evenly distrib-
uted HIV exposure.19,20
Improved estimates of product efficacy in RCTs with
more FSWs enrolled cannot be attributed to increased overall
HIV incidence in the cohort, but rather to larger proportions
of participants with consistently high HIV exposure.
Improved efficacy estimates provide an additional benefit
by reducing the likelihood of the RCT to report inconclusive
results, especially when the product is moderately effective in
reducing the risk of HIV infection per exposed sex act.
FIGURE 4. Projected impact of FSW enrollment in RCTs assuming 50% true efficacy per exposed act. A, projected HIV incidence rate
by arm; (B) projected trial duration; (C) estimated efficacy; and (D) proportion of simulated trials in which the 95% CI of the efficacy
estimate includes 0 or the predefined low efficacy limit of 25%. Five percent annual dropout rate is assumed over the course of the
trial. Box plots and whiskers represent quartile ranges and 90% UI, reflecting the estimated variation over 1000 trials simulated.
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Given that FSWs in some settings are a highly mobile
population, consideration must be given to the potential for
low retention of FSW in RCTs. In trials such as FEM-PrEP,
which included approximately 10% of enrolled women
reporting sex work or transactional sex at baseline, retention
was over 85%.16 Similarly, an HIV-negative cohort of South
African women in which 79% reported sex work and
transactional sex at baseline had 87% retention among all
participants.12 Our analysis suggested that most of the
reductions in trial duration and efficacy biases afforded by
FSW enrollment will be preserved even if dropout rates
among FSW are high. Within our model, which assumed
FSWs were missing at random, up to 50% annual loss to
follow-up among FSW participants had little effect on the
trial outcomes because its negative impact on duration and
accuracy was compensated by the positive impact of enrolling
participants with higher HIV incidence and equally exposed
to HIV. Despite that the potential for poor retention in RCTs
is always a concern and therefore, enrollment of FSW into
trials must be accompanied by efforts to maximize retention.
The support that our study provides for FSW-focused
RCT enrollment has several caveats. First, not all FSWs have
the same HIV risk. In Zimbabwe, estimated HIV incidence
among FSW is 10–12 times higher than in the general
population.33,34 However, in India, Thailand, and Benin,
targeted scale-up of condom interventions has reduced the
risk of HIV in FSW to levels comparable with that of the
general population.35,36 In some high HIV-prevalence set-
tings, the HIV incidence among women enrolled in previous
trials was already so high (nearly 10%) that enrolling FSW
would not necessary benefit a trial.37 Our analysis suggested
that the extent to which enrolling FSWs may reduce trial
duration by increasing HIV incidence depends on the
difference in HIV incidence among FSWs and non-FSWs.
Second, enrolling FSW could result in poor product perfor-
mance because of factors associated with extreme exposure to
HIV, leading to rejection of a prevention product that would
have reasonable benefit to a lower risk population. FSWs
frequently engaging in unprotected sex with clients are more
likely to be exposed to HIV variants resistant to the
prevention product compared with non-FSW. Other STDs
that cause inflammation, common in FSW, may also reduce
product efficacy. Finally, highly sexually active FSWs are
more likely to be exposed to HIV during a window of time
when product concentration falls below a protective thresh-
old, such as when long-lasting prevention products are tested.
That may lead to apparent product failure, highlighting the
need for prespecified subgroup analysis.
The ability to recruit a substantial number of FSW in
trials will depend on the size of the FSW population in the
setting of interest, their relationship with the larger commu-
nity, and the existence of programs which offer other HIV
prevention services to FSW. Therefore, site-specific data with
reliable population size estimates of FSW and information
about local epidemiological, demographic, social, and behav-
ioral factors would provide important insights on effective
methods for recruiting FSW at risk of HIV.
Our study has several limitations. We did not account
for the disclosure of HIV status by male partners and its
influence on sexual behavior, condom use, and adherence to
HIV prevention products. Results from RCTs of oral PrEP in
serodiscordant couples and in individually enrolled women
suggest that knowledge of the partners’ HIV status could be
a strong incentive to take PrEP consistently. The likelihood of
suboptimal PrEP adherence among FSW is uncertain. One
trial, FEM-PrEP, reported no significant relationship
between transactional sex and PrEP adherence.15 Including
FSW in future trials will allow for addressing the question
of differential adherence and acceptability between FSW
and non-FSW and performing subgroup analyses within
the same epidemic settings. At present, our analysis may
be most relevant to RCTs with directly observed therapy,
such as long-lasting injections and monoclonal antibody
infusions, where adherence within trial cohorts is not
an issue.
Important in this strategy, FSW and other local
populations would greatly benefit from novel HIV pre-
vention products that prove successful in an RCT; in many
settings, HIV-infected FSWs offer disproportionate risk of
the spread of HIV, so prevention of infection in this
population is particularly important. Regardless of the
potential challenges of recruiting and retaining FSW,
enrolling FSW in HIV prevention trials has considerable
advantages for trial design and validity, along with benefits
for the study subjects. Our analysis quantifies these
potential trial advantages, including faster completion,
better estimates of the true product efficacy, and a reduced
likelihood for inconclusive results.
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